Add to my selection

LUTATHERA

Medicine - Posted on Nov 23 2022

Active substance (DCI)

lutécium (177Lu) oxodotréotide

history (3)

6/29/22

LUTATHERA (177 Lutécium oxodotréotide) - TNE intestinales

Key points Approval of reimbursement only for the treatment of well-differentiated (G1 and G2), progressive, inoperable or m...

CAV :
54321

icône flèche
9/21/22

LUTATHERA (177 Lutécium oxodotréotide) - TNE pancréatiques

Key points Approval of reimbursement only for the treatment of unresectable or metastatic, progressive, well-differentiated ...

CAV :
54321

icône flèche
7/11/18

LUTATHERA (177Lutetium oxodotreotide), radiopharmaceutical

Important clinical benefit in well-differentiated (G1 and G2), progressive, unresectable or metastatic intestinal neuroendoc...

CAV :
54321

icône flèche

Technical information

ATC code

V10XX04

Manufacturer

ADVANCED ACCELERATOR APPLICATIONS

Presentation

LUTATHERA 370 mbq/ml, solution pour perfusion (code CIS : 60823764)
1 flacon(s) en verre de 20,5 à 25,0 mL de solution - (Code CIP : 34009 550 443 3 8)

All our publications

Digestive system cancers

Drug therapy

My account

You do not have a saved search

LUTATHERA

LUTATHERA (177 Lutécium oxodotréotide) - TNE intestinales

LUTATHERA (177 Lutécium oxodotréotide) - TNE pancréatiques

LUTATHERA (177Lutetium oxodotreotide), radiopharmaceutical

Follow us :